Solanezumab (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Solanezumab" in Italian language version.

refsWebsite

Global rank Italian rank

2^nd place

7^th place

4^th place

9^th place

799^th place

22^nd place

2clinicaltrials.gov

5,225^th place

5,296^th place

1web.archive.org

1^st place

1^st place

222^nd place

243^rd place

low place

low place

clinicaltrials.gov

(EN) Studio clinico NCT00905372: Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION), su ClinicalTrials.gov. URL consultato il 13 marzo 2023.
(EN) Studio clinico NCT01900665: Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo, su ClinicalTrials.gov. URL consultato il 13 marzo 2023.

doi.org

dx.doi.org

(EN) Martin Farlow et al., Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, in Alzheimer's & Dementia, vol. 8, 5 juin 2012, DOI:10.1016/j.jalz.2011.09.224. URL consultato il 13 marzo 2023.
(EN) Margaret McCartney, The "breakthrough" drug that's not been shown to help in Alzheimer's disease, in BMJ, vol. 351, luglio 2015, DOI:10.1136/bmj.h4064, PMID 26208710.
(EN) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, in The Lancet. Neurology, vol. 12, n. 4, aprile 2013, pp. 357–367, DOI:10.1016/S1474-4422(13)70044-9, PMID 23477989.
(EN) Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies, in Scientific Reports, vol. 5, aprile 2015, p. 9649, DOI:10.1038/srep09649, PMID 25880481.
(EN) Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?, in Acta Neuropathologica, vol. 127, n. 6, 2014, pp. 803–810, DOI:10.1007/s00401-014-1290-2, PMID 24803227.
(EN) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, in Proceedings of the National Academy of Sciences of the United States of America, vol. 98, n. 15, luglio 2001, pp. 8850–8855, DOI:10.1073/pnas.151261398, PMID 11438712.
(EN) Abnormal ventilatory responses in adults born prematurely, in The New England Journal of Medicine, vol. 370, n. 6, febbraio 2014, pp. 584–585, DOI:10.1056/nejmx140041, PMID 24499235.
(EN) Sperling, Donohue, Raman, Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals, in JAMA Neurology, vol. 77, n. 6, 2020, pp. 735–745, DOI:10.1001/jamaneurol.2020.0387, PMID 32250387.
(EN) Insel, Donohue, Sperling, The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults, in Annals of Clinical and Translational Neurology, vol. 7, n. 5, 2020, pp. 776–785, DOI:10.1002/acn3.51048, PMID 32315118,.

lilly.com

investor.lilly.com

(EN) Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, su Eli Lilly, Eli Lilly and Company. URL consultato il 23 novembre 2016.

nih.gov

ncbi.nlm.nih.gov

(EN) Margaret McCartney, The "breakthrough" drug that's not been shown to help in Alzheimer's disease, in BMJ, vol. 351, luglio 2015, DOI:10.1136/bmj.h4064, PMID 26208710.
(EN) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, in The Lancet. Neurology, vol. 12, n. 4, aprile 2013, pp. 357–367, DOI:10.1016/S1474-4422(13)70044-9, PMID 23477989.
(EN) Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies, in Scientific Reports, vol. 5, aprile 2015, p. 9649, DOI:10.1038/srep09649, PMID 25880481.
(EN) Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?, in Acta Neuropathologica, vol. 127, n. 6, 2014, pp. 803–810, DOI:10.1007/s00401-014-1290-2, PMID 24803227.
(EN) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, in Proceedings of the National Academy of Sciences of the United States of America, vol. 98, n. 15, luglio 2001, pp. 8850–8855, DOI:10.1073/pnas.151261398, PMID 11438712.
(EN) Abnormal ventilatory responses in adults born prematurely, in The New England Journal of Medicine, vol. 370, n. 6, febbraio 2014, pp. 584–585, DOI:10.1056/nejmx140041, PMID 24499235.
(EN) Sperling, Donohue, Raman, Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals, in JAMA Neurology, vol. 77, n. 6, 2020, pp. 735–745, DOI:10.1001/jamaneurol.2020.0387, PMID 32250387.
(EN) Insel, Donohue, Sperling, The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults, in Annals of Clinical and Translational Neurology, vol. 7, n. 5, 2020, pp. 776–785, DOI:10.1002/acn3.51048, PMID 32315118,.

pubmed.ncbi.nlm.nih.gov

(EN) Martin Farlow et al., Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, in Alzheimer's & Dementia, vol. 8, 5 juin 2012, DOI:10.1016/j.jalz.2011.09.224. URL consultato il 13 marzo 2023.

oadoi.org

(EN) Margaret McCartney, The "breakthrough" drug that's not been shown to help in Alzheimer's disease, in BMJ, vol. 351, luglio 2015, DOI:10.1136/bmj.h4064, PMID 26208710.
(EN) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, in The Lancet. Neurology, vol. 12, n. 4, aprile 2013, pp. 357–367, DOI:10.1016/S1474-4422(13)70044-9, PMID 23477989.
(EN) Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies, in Scientific Reports, vol. 5, aprile 2015, p. 9649, DOI:10.1038/srep09649, PMID 25880481.
(EN) Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?, in Acta Neuropathologica, vol. 127, n. 6, 2014, pp. 803–810, DOI:10.1007/s00401-014-1290-2, PMID 24803227.
(EN) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease, in Proceedings of the National Academy of Sciences of the United States of America, vol. 98, n. 15, luglio 2001, pp. 8850–8855, DOI:10.1073/pnas.151261398, PMID 11438712.
(EN) Abnormal ventilatory responses in adults born prematurely, in The New England Journal of Medicine, vol. 370, n. 6, febbraio 2014, pp. 584–585, DOI:10.1056/nejmx140041, PMID 24499235.
(EN) Sperling, Donohue, Raman, Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals, in JAMA Neurology, vol. 77, n. 6, 2020, pp. 735–745, DOI:10.1001/jamaneurol.2020.0387, PMID 32250387.
(EN) Insel, Donohue, Sperling, The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults, in Annals of Clinical and Translational Neurology, vol. 7, n. 5, 2020, pp. 776–785, DOI:10.1002/acn3.51048, PMID 32315118,.

web.archive.org

(EN) Drug Information (PDF), su Organizzazione mondiale della sanità. URL consultato il 13 marzo 2023 (archiviato dall'url originale il 29 agosto 2021).

wiley.com

doi.wiley.com

(EN) Eric R. Siemers, Karen L. Sundell, Christopher Carlson et Michael Case, Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients, in Alzheimer's & Dementia, vol. 12, n. 2, febbraio 2016, pp. 110-120. URL consultato il 9 giugno 2021.